Welcome to Algiax

Algiax Pharmaceuticals GmbH is an independent biotechnology company that was established in April 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.

In the field of nervous system disease, Algiax has a strong focus on neuropathic pain and acute spinal cord injury. Algiax’ lead candidate AP-325 is in clinical development for the treatment of neuropathic pain and acute spinal cord injury. A selection of new chemical entities (AP-4 & AP-8) is in preclinical development for the treatment of Diabetes Type 1.

Algiax’ strategy is to develop its drug candidates up to a Clinical Phase II-III stage and out-license them to pharmaceutical and biotech companies for further clinical development and market authorization.